WO2004081046A3 - Nouvelle composition - Google Patents

Nouvelle composition Download PDF

Info

Publication number
WO2004081046A3
WO2004081046A3 PCT/EP2004/002640 EP2004002640W WO2004081046A3 WO 2004081046 A3 WO2004081046 A3 WO 2004081046A3 EP 2004002640 W EP2004002640 W EP 2004002640W WO 2004081046 A3 WO2004081046 A3 WO 2004081046A3
Authority
WO
WIPO (PCT)
Prior art keywords
atherosclerosis
therapy
monoclonal antibodies
human monoclonal
antibodies against
Prior art date
Application number
PCT/EP2004/002640
Other languages
English (en)
Other versions
WO2004081046A2 (fr
Inventor
Pascal Mettens
Rene Meykens
Philippe Monteyne
Torbjoern Schioett
Leif Strandberg
Original Assignee
Glaxosmithkline Biolog Sa
Bioinvent Internat A B
Pascal Mettens
Rene Meykens
Philippe Monteyne
Torbjoern Schioett
Leif Strandberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa, Bioinvent Internat A B, Pascal Mettens, Rene Meykens, Philippe Monteyne, Torbjoern Schioett, Leif Strandberg filed Critical Glaxosmithkline Biolog Sa
Publication of WO2004081046A2 publication Critical patent/WO2004081046A2/fr
Publication of WO2004081046A3 publication Critical patent/WO2004081046A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention se rapporte à de nouvelles thérapies et traitements des maladies artérioslérotiques. On prévoit à cet effet des méthodes de traitement ou de prévention de l'artériosclérose par vaccination passive au moyen d'administration à un patient d'un anticorps humain apte à se lier à des fragments spécifiques d'ApoCIII. Les anticorps monoclonaux humains spécifiques et leur utilisation dans la thérapie de l'artériosclérose font également l'objet de cette invention. L'invention concerne par ailleurs l'utilisation des anticorps de cette invention dans le domaine médical.
PCT/EP2004/002640 2003-03-13 2004-03-11 Nouvelle composition WO2004081046A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0305790.8A GB0305790D0 (en) 2003-03-13 2003-03-13 Novel Composition
GB0305790.8 2003-03-13

Publications (2)

Publication Number Publication Date
WO2004081046A2 WO2004081046A2 (fr) 2004-09-23
WO2004081046A3 true WO2004081046A3 (fr) 2005-02-17

Family

ID=9954729

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/002640 WO2004081046A2 (fr) 2003-03-13 2004-03-11 Nouvelle composition

Country Status (2)

Country Link
GB (1) GB0305790D0 (fr)
WO (1) WO2004081046A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23736A1 (es) 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
EP2332995A1 (fr) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralisation d'anticorps récepteurs de prolactine et leur utilisation thérapeutique
US9783600B2 (en) 2013-02-25 2017-10-10 Imbp Holding, Llc Apolipoprotein C3 (ApoCIII) antagonists and methods of their use to remove ApoCIII inhibition of lipoprotein lipase (LPL)
CN106810606A (zh) * 2015-11-27 2017-06-09 西藏自治区人民医院 一种载脂蛋白c-ⅲ抗原多肽及其多克隆抗体的制备与应用
AU2017292184A1 (en) 2016-07-08 2019-02-07 Staten Biotechnology B.V. Anti-Apoc3 antibodies and methods of use thereof
JP2020517242A (ja) 2017-04-21 2020-06-18 スターテン・バイオテクノロジー・ベー・フェー 抗ＡｐｏＣ３抗体およびその使用方法
CN111315772A (zh) 2017-10-31 2020-06-19 斯塔顿生物技术有限公司 抗apoc3抗体及其使用方法
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
KR20210070300A (ko) * 2018-10-03 2021-06-14 스태튼 바이오테크놀로지 비.브이. 사람 및 시노몰구스 ApoC3에 대해 특이적인 항체 및 이의 사용 방법
WO2021119482A1 (fr) 2019-12-13 2021-06-17 Progenity, Inc. Dispositif ingérable pour administrer un agent thérapeutique dans le tractus gastro-intestinal

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064008A2 (fr) * 2000-03-03 2001-09-07 Smithkline Beecham Biologicals S.A. Vaccins
WO2002098919A2 (fr) * 2001-06-05 2002-12-12 Genfit Nouvelle methode de mesure de apo ciii dans des particules contenant apo b et des particules exemptes de apo b
WO2003020765A2 (fr) * 2001-08-31 2003-03-13 Glaxosmithkline Biologicals S.A. Vaccins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064008A2 (fr) * 2000-03-03 2001-09-07 Smithkline Beecham Biologicals S.A. Vaccins
WO2002098919A2 (fr) * 2001-06-05 2002-12-12 Genfit Nouvelle methode de mesure de apo ciii dans des particules contenant apo b et des particules exemptes de apo b
WO2003020765A2 (fr) * 2001-08-31 2003-03-13 Glaxosmithkline Biologicals S.A. Vaccins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ENGBERG J ET AL: "PHAGE-DISPLAY LIBRARIES OF MURINE AND HUMAN ANTIBODY FAB FRAGMENTS", NUCLEIC ACID PROTOCOLS HANDBOOK, XX, XX, 2000, pages 449 - 478, XP001037201 *
MARGET M ET AL: "BYPASSING HYBRIDOMA TECHNOLOGY: HLA-C REACTIVE HUMAN SINGLE-CHAIN ANTIBODY FRAGMENTS (SCFV) DERIVED FROM A SYNTHETIC PHAGE DISPLAY LIBRARY (HUCAL) AND THEIR POTENTIAL TO DISCRIMINATE HLA CLASS I SPECIFICITIES", TISSUE ANTIGENS, MUNKSGAARD, COPENHAGEN, DK, vol. 56, no. 1, July 2000 (2000-07-01), pages 1 - 9, XP000971781, ISSN: 0001-2815 *

Also Published As

Publication number Publication date
GB0305790D0 (en) 2003-04-16
WO2004081046A2 (fr) 2004-09-23

Similar Documents

Publication Publication Date Title
HUS1600042I1 (hu) Anti-CS1 antitestek terápiás alkalmazása
WO2005102387A3 (fr) Utilisation therapeutique des anticorps anti-cs1
WO2003090686A3 (fr) Utilisation de proteines de choc thermique pour ameliorer l'avantage therapeutique d'une modalite de traitement non vaccinal
WO2005047331A3 (fr) Anticorps liant un recepteur de l'interleucine 4
NZ617083A (en) Combination therapy for the treatment of ocular neovascular disorders
WO2004016750A3 (fr) Anticorps specifiques du recepteur fc$g(g)riib et procedes d'utilisation de ces anticorps
NZ591362A (en) Multiple-variable dose regimen for treating tnfa-related disorders
PL401886A1 (pl) Neutralizujace o wysokim powinowactwie izolowane ludzkie przeciwcialo anty-TNF-alfa, zastosowanie tego przeciwciala, krysztal zawierajacy ludzkie przeciwcialo anty-TNF-alfa i preparat zawierajacy ten krysztal
WO2004081046A3 (fr) Nouvelle composition
WO2003020765A3 (fr) Vaccins
MY146533A (en) Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
WO2000040229A3 (fr) Reponse tumoricide synergique induite par l'histamine
WO2004080375A3 (fr) Vaccin
EP0795332A3 (fr) Utilisation médicale de gamma interféron dans les maladies pulmonaires interstitielles
WO2004030607A3 (fr) Therapie d'immunisation passive a base peptidique pour le traitement de l'atherosclerose
WO2004081045A3 (fr) Vaccin
WO2003097082A3 (fr) Traitement de la maladie de crohn ou du psoriasis a partir d'anticorps anti-interferon gamma
WO2004031354A3 (fr) Antigenes associes au sarcome humain
BRPI0510052A (pt) composição, preparação combinada, métodos para a fabricação de um medicamento para o tratamento de infecções fúngicas do corpo humano ou de animal e para o tratamento de infecções fúngicas do corpo humano ou de animal, uso de uma composição, e, kit
WO2004053064A3 (fr) Fragment fab' génétiquement modifié anti-facteur de nécrose tumorale alpha combiné à des médicaments antirhumatismaux modifiant l'évolution de la maladie
WO2003034977A3 (fr) Polytherapie pour le traitement de maladie

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase